Daiichi Sankyo Co., Ltd.

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-31 EDT			5-day change	1st Jan Change
5,578 ^JPY	+3.32%		+2.46%	+44.06%

05-28	RevolKa Signs Master Service Agreement with Daiichi Sankyo	CI
05-27	AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients	DJ

Daiichi Sankyo Company, Limited Announces Management Changes

April 25, 2019 at 03:00 am

Daiichi Sankyo Company, Limited announced that Dr. Koga succeeded the position of the Head of R&D from Dr. Glenn Gormley in April 2019.

Latest news about Daiichi Sankyo Co., Ltd.

RevolKa Signs Master Service Agreement with Daiichi Sankyo	05-27	CI
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients	05-27	DJ
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial	05-27	MT
AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival	05-27	MT
Astra, Daiichi hail positive survival data for Dato-DXd	05-27	AN
Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial	05-27	CI
Jefferies Adjusts Daiichi Sankyo’s Price Target to 6,600 Yen From 5,600 Yen, Keeps at Buy	05-24	MT
AstraZeneca to build $1.5-bln cancer drug plant in Singapore	05-20	RE
Merck to present new oncology data	05-15	CF
IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court	05-15	MT
Japan's Nikkei closes at 3-week high on US rate-cut outlook, tech boost	05-07	RE
Japan's Nikkei climbs on Fed rate-cut outlook, tech boost	05-06	RE
Remsons, Daiichi Infotainments Form Joint Venture	04-30	MT
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement	04-29	MT
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow	04-29	CI
AstraZeneca makes progress with Truqap and Enhertu cancer treatments	04-29	AN
AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study	04-29	MT
Hipgnosis Songs Fund backs new Blackstone bid	04-29	AN
Scholz pledges further support for the pharmaceutical industry	04-25	DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024	04-25	MT
AstraZeneca upbeat as cancer drugs underpin sales growth	04-25	AN
Transcript : Daiichi Sankyo Company, Limited, 2024 Earnings Call, Apr 25, 2024	04-25
Daiichi Sankyo Company, Limited Announces Dividend for the Year Ended March 31, 2024, Payable on June 18, 2024 and Provides Dividend Guidance for Second Quarter of Fiscal Ending March 31, 2025	04-25	CI
Daiichi Sankyo Company, Limited Provides Dividend Guidance for Full Fiscal Ending March 31, 2025	04-25	CI
Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2025	04-25	CI

Chart Daiichi Sankyo Co., Ltd.

Duration

Period

More charts

Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).

Sector

Pharmaceuticals

Calendar

2024-06-01 - American Society of Clinical Oncology Meeting - Abstract No TPS3165

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5,399 JPY

Average target price

5,977 JPY

Spread / Average Target

+10.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAIICHI SANKYO CO., LTD.	+44.06%	66.06B
ELI LILLY AND COMPANY	+39.62%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.45%	350B
MERCK & CO., INC.	+16.00%	315B
ABBVIE INC.	+1.93%	276B
ASTRAZENECA PLC	+14.98%	238B
NOVARTIS AG	+9.38%	206B
ROCHE HOLDING AG	-5.36%	204B
AMGEN INC.	+5.69%	161B

Other Pharmaceuticals

Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Pharmaceuticals

Daiichi Sankyo Company, Limited Announces Management Changes

Latest news about Daiichi Sankyo Co., Ltd.

Chart Daiichi Sankyo Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Daiichi Sankyo Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals